钠-葡萄糖协同转运蛋白2抑制剂与肺炎及感染性休克风险
该研究系统检索了MEDLINE、Embase和ClinicalTrials.gov截至2022年5月19日的随机安慰剂对照试验,纳入26项试验共59264例糖尿病患者。与安慰剂相比,SGLT2i显著降低肺炎风险(汇总RR 0.87,95%CI 0.78-0.98)和感染性休克风险(汇总RR 0.65,95%CI 0.44-0.95),作者认为该发现为假设生成性,需未来研究验证。
要点
- SGLT2i较安慰剂降低肺炎风险(汇总RR 0.87,95%CI 0.78-0.98)。
- SGLT2i较安慰剂降低感染性休克风险(汇总RR 0.65,95%CI 0.44-0.95)。
- 作者认为该发现为假设生成性,相关概念需未来研究验证。
核心结论
- 在糖尿病患者中,与安慰剂相比,SGLT2i降低肺炎和感染性休克风险;作者认为该发现为假设生成性,相关概念需未来研究验证。
研究设计与样本
- 系统检索MEDLINE、Embase和ClinicalTrials.gov自建库至2022年5月19日的随机安慰剂对照试验,纳入报告肺炎和/或感染性休克结局的糖尿病患者,由独立作者进行研究选择、数据提取和质量评价(使用Cochrane偏倚风险评估工具),采用固定效应模型汇总相对风险(RR)及95%CI。
- 共纳入26项试验,总计59264例患者,其中1.9%发生肺炎、0.2%发生感染性休克。
主要发现
- 从4568条引文中纳入26项试验共59264例患者,1.9%发生肺炎、0.2%发生感染性休克。
- 与安慰剂相比,SGLT2i显著降低肺炎风险(汇总RR 0.87,95%CI 0.78-0.98)。
- 与安慰剂相比,SGLT2i显著降低感染性休克风险(汇总RR 0.65,95%CI 0.44-0.95)。
- 试验间效应量无显著异质性。
- 按SGLT2i类型、基线合并症、血糖控制、糖尿病病程和试验随访时间进行的亚组分析结果一致,无显著治疗-by-亚组交互异质性(所有Pheterogeneity > .10)。
局限性
- 作者认为该发现为假设生成性,相关概念需未来研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Individuals with type 2 diabetes mellitus (DM) have an increased risk of pneumonia and septic shock. Traditional glucose-lowering drugs have recently been found to be associated with a higher risk of infections. It remains unclear whether sodium-glucose cotransporter 2 inhibitors (SGLT2is), which have pleiotropic/anti-inflammatory effects, may reduce the risk of pneumonia and septic shock in DM. METHODS: MEDLINE, Embase, and ClinicalTrials.gov were searched from inception up to May 19, 2022, for randomized, placebo-controlled trials of SGLT2i that included patients with DM and reported outcomes of interest (pneumonia and/or septic shock). Study selection, data extraction, and quality assessment (using the Cochrane Risk of Bias Assessment Tool) were conducted by independent authors. A fixed-effects model was used to pool the relative risk (RRs) and 95% CI across trials. RESULTS: Out of 4568 citations, 26 trials with a total of 59 264 patients (1.9% developed pneumonia and 0.2% developed septic shock) were included. Compared with placebo, SGLT2is significantly reduced the risk of pneumonia (pooled RR 0.87, 95% CI 0.78-0.98) and septic shock (pooled RR 0.65, 95% CI 0.44-0.95). There was no significant heterogeneity of effect size among trials. Subgroup analyses according to the type of SGLT2i used, baseline comorbidities, glycemic control, duration of DM, and trial follow-up showed consistent results without evidence of significant treatment-by-subgroup heterogeneity (all Pheterogeneity > .10). CONCLUSION: Among DM patients, SGLT2is reduced the risk of pneumonia and septic shock compared with placebo. Our findings should be viewed as hypothesis generating, with concepts requiring validation in future studies.
引用
- Li HL, Tse YK, Chandramouli C, et al. Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock. J Clin Endocrinol Metab. 2022. PMID: 36181458. doi:10.1210/clinem/dgac558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。